

**THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION.**

If you are in any doubt as to what action to take, you should consult your stockbroker, solicitor, accountant or other appropriate independent professional adviser authorised under the Financial Services and Markets Act 2000. If you have sold or otherwise transferred all your shares in Ergomed plc, please forward this document and the accompanying form of proxy to the person through whom the sale or transfer was effected, for transmission to the purchaser or transferee.



Ergomed plc  
**Notice of Annual General Meeting**

to be held at 9.30 a.m. on Thursday, 10 June 2021 at 80 Coleman Street, London, EC2R 6PA

**Ergomed plc**  
1 Occam Court  
Surrey Research Park  
Guildford  
Surrey  
GU2 7HJ

Incorporated in England and Wales with registered number 04081094

14 May 2021

Dear Shareholder,

## 2021 Annual General Meeting

I am pleased to enclose notice of the Annual General Meeting ("AGM") of Ergomed plc ("Company"), which will be held at 9.30 a.m. on Thursday, 10 June 2021 at 80 Coleman Street, London, EC2R 6PA.

### COVID-19

At the time of publication of the Notice of AGM, the UK Government has imposed restrictions on gatherings and social contact due to the COVID-19 situation. These restrictions may remain in place at the time of the AGM to be held on 10 June 2021. Therefore, in order to comply with the UK government's measures, and to ensure the safety of the Company's shareholders and the wider community, at the date of this document the AGM is intended to be run as a closed meeting, with shareholders not being able to attend in person. Only a minimum number of people will attend the meeting in person, in order to satisfy the quorum requirements.

We will continue to monitor the situation as we approach the AGM. The UK Government's roadmap for easing lockdown restrictions in England published on 22 February 2021 envisages the potential for indoor events of up to 1,000 people or half a venue's capacity (if lower) to take place no earlier than 17 May 2021. However, this is subject to a number of contingencies and there can be no guarantee that this will happen. If restrictions have eased in sufficient time and circumstances enable it, we will seek to change the venue to permit shareholders to attend the meeting in person if they wish. Any changes will be made in line with the UK Government's guidance and with health and safety as a priority. We expect that there will continue to be some social distancing restrictions in place on the date of the AGM that will continue to have a significant impact on our arrangements, including the number of permitted attendees in person and how the AGM is conducted. We therefore still recommend that shareholders do not attend in person and encourage them to use their right to appoint the Chairman of the AGM as their proxy, to ensure that their votes can be exercised at the AGM. Further details are set out in the explanatory notes to the Notice of AGM.

It is very important to the Company that shareholders have the opportunity to raise any questions they may have, and shareholders are therefore encouraged to submit any questions in advance of the AGM by e-mail to [ir@ergomedplc.com](mailto:ir@ergomedplc.com). We will publish these questions (other than any questions which the Board considers to be frivolous or vexatious) and answers on our website following the AGM.

Shareholders should continue to monitor the Company's website and announcements for any updates in relation to the AGM, and we thank shareholders for their support in relation to the alternative arrangements at this year's AGM.

### Resolutions to be proposed at the AGM

Set out below is an explanation of the resolutions set out in the Notice of AGM. Resolutions 1 to 5 are proposed as ordinary resolutions. This means that for each of those resolutions to be passed, more than half of the votes cast must be in favour of the resolution. Resolutions 6 and 7 are proposed as special resolutions. This means that for these resolutions to be passed, at least three quarters of the votes cast must be in favour of the resolution.

#### Resolution 1 – Report and accounts

Resolution 1 proposes that the Company's annual accounts for the year ended 31 December 2020, together with the directors' report and the auditor's report on these accounts, be received and adopted.

#### Resolution 2 – Reappointment of auditors

Resolution 2 relates to the reappointment of KPMG, Dublin, as the Company's auditors to hold office until the next Annual General Meeting of the Company and to authorise the directors to set their remuneration.

### **Resolutions 3 and 4 – Reappointment of directors**

Dr. Llew Keltner (Non-executive Director) has been appointed as a director since the Company's last Annual General Meeting and is required to offer himself for reappointment in accordance with the Company's Articles of Association. Resolution 3 will therefore be proposed to reappoint Llew Keltner as a director.

The Company's Articles of Association require one third of eligible directors to retire at each Annual General Meeting, being those director(s) that have been longest in office since their last appointment. Because Llew Keltner is proposed for reappointment as explained above, he is not included in the calculation of determining which director(s) have to retire and seek reappointment. Richard Barfield and Rolf Soderstrom were reappointed at the Company's last Annual General Meeting, and Michael Spiteri was reappointed at the Company's Annual General Meeting held in 2019. This means that I, Miroslav Reljanović, am required to retire and offer myself for reappointment, as reflected in Resolution 4.

Biographies of all directors are set out on the Company's website at [www.ergomedplc.com](http://www.ergomedplc.com).

### **Resolution 5 – Authority to allot shares**

Your directors may only allot shares or grant rights over shares if authorised to do so by the shareholders. The existing authorities were granted at the Company's Annual General Meeting held on 10 June 2020 and those authorities are due to expire at the Company's Annual General Meeting in 2021 or on 10 September 2021, whichever is the earlier, and therefore require renewal. Resolution 5 will therefore be proposed as an ordinary resolution to grant a new authority to allot unissued share capital up to an aggregate nominal value of £162,512, representing approximately one third of the Company's issued ordinary share capital as at 30 April 2021 (being the latest practicable date prior to publication of the Notice of AGM) and a further authority to allot unissued share capital up to an aggregate nominal value of £162,512, provided that such authority to allot is reserved for rights issues (in accordance with The Investment Association Guidelines). This authority, if given, will expire on the earlier of the conclusion of the Company's next Annual General Meeting or on the date which is 15 months after the relevant resolution is passed.

### **Resolution 6 – Disapplication of statutory pre-emption rights**

Resolution 6 will be proposed as a special resolution to disapply statutory pre-emption rights in respect of the allotment or granting of rights over shares for cash. The authority will be limited to an offer to existing shareholders pro-rata to their holdings and the issue of shares to a maximum aggregate nominal value of £24,376, which represents no more than 5% of the Company's issued ordinary share capital as at 30 April 2021 (being the latest practicable date prior to publication of the Notice of AGM). This authority is consistent with the Pre-Emption Group's revised Statement of Principles on Disapplying Pre-emption Rights which was published on 12 March 2015. This authority, if given, will expire on the earlier of the conclusion of the Company's next Annual General Meeting or on the date which is 15 months after the relevant resolution is passed.

### **Resolution 7 – Disapplication of statutory pre-emption rights in connection with an acquisition or other capital investment**

Resolution 7 will be proposed as a special resolution to, in addition to resolution 6, disapply statutory pre-emption rights in respect of the allotment or granting of rights over shares for cash. The authority will be limited to the issue of shares to a maximum aggregate nominal value of £24,376, which represents no more than 5% of the Company's issued ordinary share capital as at 30 April 2021 (being the latest practicable date prior to publication of the Notice of AGM), for the purposes of financing an acquisition or specified capital investment (or refinancing any such acquisition or investment within six months after the date of the original transaction). This further authority is consistent with the Pre-Emption Group's revised Statement of Principles on Disapplying Pre-emption Rights which was published on 12 March 2015. This authority, if given, will expire on the earlier of the conclusion of the Company's next Annual General Meeting or on the date which is 15 months after the relevant resolution is passed.

### **Action to be taken**

Please complete and submit the form of proxy enclosed with this document in accordance with the instructions printed on the form. To be valid, the form of proxy must be received by the Company's Registrar, Share Registrars Limited, not later than 48 hours (excluding weekends and bank holidays) before the time appointed for holding the AGM. Further instructions relating to the form of proxy are set out in the explanatory notes to the Notice of AGM. Shareholders may also appoint a proxy through the CREST electronic proxy appointment service, where applicable, in accordance with the instructions in the Notice of AGM.

### **Recommendation**

Your Board believes that the resolutions to be proposed at the AGM are in the best interests of the Company and its shareholders as a whole. Accordingly, the directors unanimously recommend that shareholders vote in favour of the resolutions, as they intend to do in respect of their own beneficial holdings of shares in the Company.

Yours faithfully

### **Miroslav Reljanović**

Executive Chairman  
Ergomed plc

# ERGOMED PLC

## NOTICE OF ANNUAL GENERAL MEETING

(incorporated in England and Wales with registered number 04081094)

Notice is hereby given that the Annual General Meeting of Ergomed plc (the "**Company**") will be held at the Company's offices at 80 Coleman Street, London, EC2R 6PA at 9.30 a.m. on Thursday, 10 June 2021 to consider, and if thought fit, to pass the following resolutions. It is intended to propose resolutions 6 and 7 as special resolutions. All other resolutions will be proposed as ordinary resolutions.

1. To receive and adopt the accounts for the financial year ended 31 December 2020, together with the reports of the directors and auditor thereon.
2. To reappoint KPMG, Dublin as auditor of the Company from the conclusion of the meeting until the conclusion of the next Annual General Meeting of the Company at which accounts are laid and to authorise the directors to determine their remuneration.
3. To reappoint Llew Keltner as a director who, having been appointed by the Board in accordance with Article 30.2 of the Company's Articles of Association, is retiring and, being eligible, is offering himself for reappointment.
4. To reappoint Miroslav Reljanović as a director who, in accordance with Article 35 of the Company's Articles of Association, is retiring by rotation and, being eligible, is offering himself for reappointment.
5. That the directors be and they are hereby generally and unconditionally authorised, pursuant to Section 551 of the Companies Act 2006 (the "**Companies Act**"), to exercise all the powers of the Company:

5.1 to allot shares and grant rights to subscribe for, or convert any security into, such shares (all of which transactions are hereafter referred to as an allotment of "**relevant securities**") up to an aggregate nominal amount of £162,512; and

5.2 to allot further equity securities (within the meaning of Section 560(1) of the Companies Act) up to an aggregate nominal amount of £162,512 in connection with a rights issue in favour of shareholders where the equity securities respectively attributable to the interest of the shareholders are as proportionate (as nearly as practicable) to the respective numbers of ordinary shares held by them, which satisfies the conditions and may be subject to all or any of the exclusions specified in paragraph 6.1 of resolution 6,

provided that the authority conferred by this resolution shall expire (unless previously revoked or varied by the Company in general meeting) at the conclusion of the next Annual General Meeting of the Company or the date 15 months from the date of passing of this resolution, whichever is the earlier, save that the Company may before such expiry, revocation or variation make an offer or agreement which would or might require relevant securities to be allotted after such expiry, revocation or variation and the directors may allot relevant securities pursuant to such offer or agreement as if the authority hereby conferred had not expired or been revoked or varied. This authority is in substitution for any and all authorities previously conferred on the directors for the purposes of Section 551 of the Companies Act.

6. That the directors be given power subject to the passing of resolution 5 and in accordance with Section 570 of the Companies Act, to allot equity securities (as defined in Section 560 of the Companies Act) for cash pursuant to the authority conferred on them by resolution 5 as if Section 561 of the Companies Act did not apply to the allotment but this power shall be limited to:

6.1 the allotment of equity securities in connection with an offer or issue of equity securities (but in the case of the authority granted under paragraph 5.2 of resolution 5 by way of a rights issue only) to or in favour of:

(a) holders of ordinary shares in proportion (as nearly as may be practicable) to their existing holdings; and

(b) holders of other equity securities if this is required by the rights of those securities or, if the directors consider it necessary, as permitted by the rights of those securities,

and so that the directors may make such exclusions or other arrangements as they consider expedient or necessary in relation to fractional entitlements, record dates, shares represented by depositary receipts, legal or practical problems under the laws in any territory or the requirements of any relevant regulatory body or stock exchange or any other matter; and

6.2 the allotment of equity securities for cash pursuant to the authority granted under paragraph 5.1 of resolution 5 (otherwise than under paragraph 6.1 above) up to a maximum nominal amount of £24,376,

provided that the power conferred by this resolution is subject to the continuance of the authority conferred by resolution 5 and shall expire (unless previously revoked or varied by the Company in general meeting) at the conclusion of the next annual general meeting of the Company or the date 15 months from the date of passing of this resolution, whichever is the earlier, save that the Company may before such expiry, revocation or variation make an offer or agreement which would or might require equity securities to be allotted after such expiry, revocation or variation and the directors may allot equity securities pursuant to such offer or agreement as if the power hereby conferred had not expired or been revoked or varied. This power is in substitution for any and all powers previously conferred on the directors under Section 570 of the Companies Act.

7. That the directors be given power subject to the passing of resolution 5 and in accordance with Section 570 of the Companies Act, in addition to any power granted under resolution 6, to allot equity securities (as defined in Section 560 of the Companies Act) for cash pursuant to the authority conferred on them by resolution 5 as if Section 561 of the Companies Act did not apply to the allotment but this power shall be:

- 7.1 limited to the allotment of equity securities for cash pursuant to the authority granted under paragraph 5.1 of resolution 5 up to a maximum nominal amount of £24,376; and
- 7.2 used only for the purposes of financing (or refinancing, if the power is to be exercised within six months after the date of the original transaction) a transaction which the directors determine to be an acquisition or other capital investment of a kind contemplated by the Statement of Principles on Disapplying Pre-Emption Rights most recently published by the Pre-Emption Group prior to the date of this notice,

provided that the power conferred by this resolution is subject to the continuance of the authority conferred by resolution 5 and shall expire (unless previously revoked or varied by the Company in general meeting) at the conclusion of the next annual general meeting of the Company or the date 15 months from the date of passing of this resolution, whichever is the earlier, save that the Company may before such expiry, revocation or variation make an offer or agreement which would or might require equity securities to be allotted after such expiry, revocation or variation and the directors may allot equity securities pursuant to such offer or agreement as if the power hereby conferred had not expired or been revoked or varied. This power is in substitution for any and all powers previously conferred on the directors under Section 570 of the Companies Act.

BY ORDER OF THE BOARD

**Miroslav Reljanović**

Executive Chairman  
14 May 2021

**Registered office:**

1 Occam Court  
Surrey Research Park  
Guildford  
Surrey  
GU2 7HJ

## Explanatory notes to the Notice of Annual General Meeting

### Proxies

1. A form of proxy is enclosed for your use. As at the date of this Notice of Meeting, COVID-19 restrictions on gatherings and social contact remain in place, which would prevent persons (other than those shareholders required to constitute a quorum) from attending the meeting in person. Therefore, as it stands the meeting will be held as a closed meeting and, so, the completion and return of a proxy within the time period prescribed is strongly recommended, so that your full voting entitlement is represented at the meeting. **Due to possible attendance restrictions at the meeting, appointed proxies other than the Chairman of the Meeting may not be permitted to attend the meeting in person and, as such, you are strongly advised to appoint the Chairman of the Meeting as your proxy to ensure that your vote will count.**
2. A member of the Company entitled to attend and vote at the meeting may appoint one or more proxies to exercise all or any of his rights to attend, to speak and to vote on his/her behalf. A proxy need not be a member of the Company but shareholders' attention is drawn to the important information in these Notes regarding the ability of such proxies to attend. A member may appoint more than one proxy in relation to the meeting, provided that each proxy is appointed to exercise the rights attached to a different share or shares held by him or her. Each such proxy will have the right to vote on a poll in respect of the number of votes attaching to the number of shares in respect of which the proxy has been appointed. Where more than one joint member purports to appoint a proxy in respect of the same shares, only the appointment by the most senior member will be accepted as determined by the order in which their names appear in the Company's register of members. The instrument appointing a proxy and the power of attorney or other authority (if any) under which it is signed or a duly certified copy of that power or other authority (if any), must be completed and signed, sent or delivered to the Company's registrars, Share Registrars Limited, The Courtyard, 17 West Street, Farnham, Surrey, GU9 7DR, or scanned and emailed to [voting@shareregistrars.uk.com](mailto:voting@shareregistrars.uk.com), not later than 48 hours (excluding weekends and bank holidays) before the time of the meeting, or in the case of a poll taken subsequently to the date of the meeting, or any adjournment thereof, not less than 24 hours (excluding weekends and bank holidays) before the time appointed for the taking of the poll (and in calculating these periods no account shall be taken of any part of a day which is a Saturday, Sunday or a bank holiday in England). Please state "Ergomed plc AGM" and your name in the subject line of your email. Members who intend to appoint more than one proxy can obtain additional forms of proxy from Share Registrars Limited, or can photocopy the enclosed proxy form. Members appointing more than one proxy should return the forms of proxy in the same envelope and should indicate on each form of proxy the name of the proxy appointed and the number of ordinary shares in respect of which that proxy is appointed. If you are a CREST member, see note 6 below. **However, due to possible attendance restrictions at the meeting, you are strongly advised to appoint the Chairman of the Meeting as your proxy to ensure that your vote is counted.**
3. A vote withheld option has been included on the form of proxy. The legal effect of choosing the vote withheld option on any resolution is that the member concerned will be treated as not having voted on the relevant resolution. The number of votes in respect of which there are votes withheld will however be counted and recorded, but disregarded in calculating the number of votes for or against each resolution.
4. In order to revoke a proxy appointment, an appointing shareholder will need to inform the Company by sending a signed notice, clearly stating the intention to revoke the proxy appointment, to the Company's registrars, Share Registrars Limited, The Courtyard, 17 West Street, Farnham, Surrey GU9 7DR, or to [voting@shareregistrars.uk.com](mailto:voting@shareregistrars.uk.com), to be received at least one hour before the commencement of the meeting or adjourned meeting, or in the case of a poll taken subsequently to the meeting or adjourned meeting, by the time appointed for taking the poll. **However, due to possible attendance restrictions at the meeting, you are strongly advised to appoint the Chairman of the Meeting as your proxy to ensure that your vote is counted.**
5. In accordance with Regulation 41 of the Uncertificated Securities Regulations 2001, only those shareholders entered in the Company's register of members at 9:30 a.m. on Tuesday, 8 June 2021, or, if the meeting is adjourned, shareholders entered in the Company's register of members not later than 48 hours (excluding weekends and bank holidays) before the time of the adjourned meeting, shall be entitled to attend and vote at the meeting in respect of the number of shares registered in their name at the relevant time. Subsequent changes to entries on the register of members will be disregarded in determining the rights of any person to attend or vote at the meeting or any adjourned meeting (as the case may be).

6. CREST members who wish to appoint a proxy or proxies through the CREST electronic proxy appointment service may do so for the Annual General Meeting to be held on Thursday, 10 June 2021 at 9.30 a.m. and any adjournment(s) thereof by using the procedures described in the CREST Manual. CREST personal members or other CREST sponsored members, and those CREST members who have appointed a voting service provider(s), should refer to their CREST sponsors or voting service provider(s), who will be able to take the appropriate action on their behalf. In order for a proxy appointment or instruction made by means of CREST to be valid, the appropriate CREST message (a "**CREST Proxy Instruction**") must be properly authenticated in accordance with Euroclear UK & Ireland Limited's specifications and must contain the information required for such instructions, as described in the CREST Manual available via [www.euroclear.com/CREST](http://www.euroclear.com/CREST). The message, regardless of whether it constitutes the appointment of a proxy or an amendment to the instruction given to a previously appointed proxy, must be transmitted so as to be received by the Company's agent, Share Registrars Limited (CREST Participant ID: 7RA36), no later than 48 hours (excluding weekends and bank holidays) before the time appointed for the meeting. For this purpose, the time of receipt will be taken to be the time (as determined by the time stamp applied to the message by the CREST Application Host) from which the Company's agent is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST. After this time any change of instructions to proxies appointed through CREST should be communicated to the appointee through other means. CREST members and, where applicable, their CREST sponsor or voting service provider should note that Euroclear UK & Ireland Limited does not make available special procedures in CREST for any particular messages. Normal system timings and limitations will therefore apply in relation to the input of CREST Proxy Instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST personal member or sponsored member or has appointed a voting service provider(s), to procure that his CREST sponsor or voting service provider(s) take(s)) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection, CREST members and, where applicable, their CREST sponsor or voting service provider are referred in particular to those sections of the CREST Manual concerning practical limitations of the CREST system and timings. The Company may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001.
7. Any corporation that is a member can appoint one or more corporate representatives who have one vote each on a show of hands and otherwise may exercise on its behalf all of its powers as a member provided that they do not do so in different ways in relation to the same shares. **However, due to possible attendance restrictions at the meeting, you are strongly advised to appoint the Chairman of the Meeting as your proxy to ensure that your vote is counted.**

### Communication

8. You may not use any electronic address (within the meaning of Section 333(4) of the Companies Act 2006) provided in this Notice of Meeting (or in any related documents including the form of proxy) to communicate with the Company for any purposes other than those expressly stated.

**Ergomed plc**

1 Occam Court  
Surrey Research Park  
Guildford  
Surrey GU2 7HJ

[www.ergomedplc.com](http://www.ergomedplc.com)